Zevra Therapeutics Inc.
NASDAQ: ZVRA · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
Zevra Therapeutics Inc. (ZVRA) Financial statements
SEC filings — annual and quarterly data.
Margin trends — annual
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2012 | — | $-70416.00 | — | — | — |
| 2013 | — | $-5.23M | — | — | — |
| 2014 | — | $-24.45M | — | — | — |
| 2015 | — | $-54.66M | — | — | — |
| 2016 | — | $-16.52M | — | — | — |
| 2017 | — | $-43.39M | — | — | — |
| 2018 | — | $-56.47M | — | — | — |
| 2019 | $12.84M | $-24.52M | 77.06% | -158.40% | -191.00% |
| 2020 | $13.29M | $-12.76M | 90.18% | -42.21% | -96.03% |
| 2021 | $28.65M | $-8.55M | 92.81% | 26.98% | -29.86% |
| 2022 | $10.16M | $-26.77M | 97.82% | -418.91% | -263.48% |
| 2023 | $27.46M | $-46.05M | 89.28% | -180.63% | -167.69% |
| 2024 | $23.61M | $-105.51M | 68.59% | -368.47% | -446.85% |
| 2025 | $106.47M | $83.23M | 84.52% | -3.98% | 78.17% |
Frequently asked questions
What is Zevra Therapeutics Inc.'s revenue?
Zevra Therapeutics Inc.'s trailing twelve-month revenue is $122.29M, and consensus projects about $460.00M by 2030. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is ZVRA?
In its most recent fiscal year, ZVRA ran a gross margin of 84.52%, an operating margin of -3.98%, and a net margin of 78.17%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does ZVRA generate?
ZVRA produced $-2.43M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is ZVRA's balance sheet healthy?
ZVRA holds $62.41M in cash and equivalents against $61.93M in long-term debt, on $154.66M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.